|
|
|
21.10.25 - 13:54
|
BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study (GlobeNewswire EN)
|
|
|
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 21, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the addition of several key large cancer centers to its ongoing pivotal Phase 3 clinical study (ClinicalTrials.gov as NCT06072612), notably Dartmouth Cancer Center, Cedars-Sinai Medical Center, and Winship Cancer Institute of Emory University. BriaCell anticipates reporting top line data as early as H1-2026....
|
|
|
21.10.25 - 13:33
|
BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer (GlobeNewswire EN)
|
|
|
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 21, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce a collaboration with Memorial Sloan Kettering Cancer Center's (MSK's) Therapeutics Accelerator Cohort program to accelerate the clinical development of Bria-OTS+, BriaCell's next generation personalized off-the-shelf immunotherapy, for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers....
|
|
|
20.10.25 - 13:33
|
BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025 (GlobeNewswire EN)
|
|
|
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 20, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces encouraging clinical biomarker data in its ongoing pivotal Phase 3 study of Bria-IMT plus an immune check point inhibitor (CPI) in metastatic breast cancer. The findings are being presented in BriaCell's poster presentation at the European Society for Medical Oncology (ESMO) Congress 2025 Annual Meeting taking place October 17 – 21, 2025 in Berlin, Germany. The Phase 3 data shown is for all patients evaluated regardless of treatment assignment (i.e. is blinded)....
|
|
|
13.10.25 - 13:33
|
BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025 (GlobeNewswire EN)
|
|
|
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 13, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, will be presenting positive clinical biomarker data of its ongoing pivotal Phase 3 study of Bria-IMT plus an immune check point inhibitor (CPI) in metastatic breast cancer at its poster presentation at the European Society for Medical Oncology (ESMO) Congress 2025 Annual Meeting taking place October 17 – 21 in Berlin, Germany....
|
|
|
03.10.25 - 13:33
|
BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting (GlobeNewswire EN)
|
|
|
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that the Company will be presenting preclinical Bria-OTS+ data at a poster presentation at the Society for Immunotherapy of Cancer (SITC) 40th Anniversary Annual Meeting, held November 7-9, 2025, in National Harbor, MD. The details are listed below....
|
|
|
24.08.25 - 21:27
|
XFRA: NEW INSTRUMENT AVAILABLE - 25.08.2025 - CA1079303071 (XETRA)
|
|
|
Das Instrument 8BT CA1079303071 BRIACELL THERAPEUTICS NEW EQUITY hat seinen ersten Handelstag am 25.08.2025: CONTINUOUS AUCTION SPECIALIST, PAG PAG_EQU, SettlCurr EUR, CCP N
The instrument 8BT CA1079303071 BRIACELL THERAPEUTICS NEW EQUITY has its first trading date on 25.08.2025: CONTINUOUS AUCTION SPECIALIST, PAG PAG_EQU, SettlCurr EUR, CCP N...
|
|
|
22.08.25 - 16:54
|
XFRA: ISIN Change (XETRA)
|
|
|
Einstellung Aufnahme
ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: Anmerkungen
DE000A2YN702 UMT United Mobility Technology AG 22.08.2025 DE000A40ZVU2 UMT United Mobility Technology AG 25.08.2025 Tausch 10:1
CA8949421017 Rocket Doctor AI Inc. 22.08.2025 CA7729241066 Rocket Doctor AI Inc. 25.08.2025 Tausch 1:1
SE0017885379 Cell Impact AB 22.08.2025 SE0025940513 Cell Impact AB 25.08.2025 Tausch 10:1
US74841Q2093 Quhuo Ltd. 22.08.2025 US74841Q3083 Quhuo Ltd. 25.08.2025 Tausch 90:1
CA1079302081 Briacell Therapeutics Corp. 22.08.2025 CA1079303071 Briacell Therapeutics Corp. 25.08.2025 Tausch 10:1...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
